NCT02254668View on ClinicalTrials.gov

Intracoronary Analysis of Cardiac Allograft Vasculopathy by Means of Optical Coherence Tomography

PHASE4UnknownINTERVENTIONAL
Enrollment

278

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

February 28, 2023

Study Completion Date

February 28, 2023

Conditions
Intimal ProliferationImmunosuppression
Interventions
OTHER

Protocol with Everolimus (Certican®)

Electronic (computer-assisted) randomization of an immunosuppressive protocol WITH Everolimus (Certican®).

OTHER

Protocol with Mycophenolate mofetil (CellCept®)

Electronic (computer-assisted) randomization of an immunosuppressive protocol WITHOUT Everolimus (Certican®), instead administration of Mycophenolate mofetil (CellCept®).

Trial Locations (1)

8091

RECRUITING

University Hospital Zurich, Division of Cardiology, Zurich

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

University of Zurich

OTHER